摘要
目的探讨可溶性ST2(sST2)在婴幼儿肺炎合并急性心衰过程中的变化,为婴幼儿肺炎合并心衰的诊断及治疗提供参考依据。方法30例肺炎合并心衰患儿作为心衰组,同期就诊的30例肺炎无并发症患儿为肺炎组和30例健康婴幼儿为对照组,分别测定心衰组治疗前、肺炎组、对照组及心衰组治疗后血清sST2值。结果心衰组治疗前与肺炎组、对照组的sST2值比较,差异均具有统计学意义(P<0.01);心衰组治疗前后,即心衰期与心衰缓解期sST2值比较,差异具有统计学意义(P<0.01)。结论婴幼儿肺炎合并急性心衰时sST2值升高,治疗后sST2值明显下降,sST2参与肺炎合并心衰的发展过程,可作为婴幼儿肺炎合并急性心衰早期参考指标。
Objective To evaluate the significance of the sST2 levels in infants with pneumonia complicated with heart failure, which provides objective basis for the diagnosis and early intervention treatment of heart failure. Methods Selecting 30 cases of pneumonia complicated acute heart failure as heart failure group, 30 cases of pneumonia without acute heart failure as pneumonia group and 30 healthy infants as control group. To assess the sST2 levels of the three groups. Results The sST2 levels were statistically significant among pneumonia complicated with heart failure group, pneumonia group and the controls before treatment （P 〈 0.01）. The sST2 levels had obvious significant difference between pneumonia complicated with heart failure group before and after treatment （/9 〈 0.01）. Conclusion After treatment, the levels of sST2 in infant with pneumonia complicated with heart failure is significantly decreased, which revealed sST2 played an important roal in the development of pneumonia complicated with heart failure, and can played as an indicator for early diagnosis for pneumonia complicated with heart failure.
出处
《中国卫生标准管理》
2017年第7期57-58,共2页
China Health Standard Management
